Okey AB, Riddick DS, Harper PA. Molecular biology of the aromatic hydrocarbon
(dioxin) receptor. Trends Pharmacol Sci 1994;15:226–232.
Ourlin JC, Handschin C, Kaufmann M, Meyer UA. A Link between cholesterol levels
and phenobarbital induction of cytochromes P450. Biochem Biophys Res Commun
2002;291:378–384.
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of
CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid
receptors. Biochim Biophys Acta 2003;1619:243–253.
Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC,
Burton LA, Latham J, Nevins C, Parkinson A. Effects of freezing, thawing, and
storing human liver microsomes on cytochrome P450 activity. Arch Biochem
Biophys 1996;331:145–169.
Philip PA, Kaklamanis L, Ryley N, Stratford I, Wolf R, Harris A, Carmichael J.
Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic
tumors in man. Int J Radiat Oncol Biol Phys 1994;29:277–283.
Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P.
Cyclosporin A drug interactions. Screening for inducers and inhibitors of
cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes
and in liver microsomes. Drug Metab Dispos 1990;18:595–606.
Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C,
Eisenhandler R, Carlini EJ. Comparative effects of fibrates on drug metabolizing
enzymes in human hepatocytes. Pharm Res 2005;22:71–78.
Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative
effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-
transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol
Interact 1999;121:37–48.
Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, de Morais SM. Use
of immortalized human hepatocytes to predict the magnitude of clinical drug–drug
interactions caused by CYP3A4 induction. Drug Metab Dispos 2006;34:1742–1748.
Ronis MJ, Ingelman-Sundberg M. Induction of human drug metabolizing enzymes:
mechanisms and implications. In: Woolf TF, editor. Handbook of Drug Metabolism.
New York: Marcel Dekker; 1999 p 239–262.
Roymans D, van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD,
Koganti A, Gilissen R, Silber P, Mannens G, Meuldermans W. Determination of
cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human
hepatocytes. Biochem Pharmacol 2004;67:427–437.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD,
Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using
bicinchoninic acid. Anal Biochem 1985;150:76–85.
Sotaniemi EA, Rautio A, Backstrom M, Arvela P, Pelkonen O. CYP3A4 and
CYP2A6 activities marked by the metabolism of lignocaine and coumarin in
patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol
1995;39:71–76.
Strom SC, Jirtle RL, Jones RS, Novicki DL, Rosenberg MR, Novotny A, Irons G,
McLain JR, Michalopoulos G. Isolation, culture, and transplantation of human
hepatocytes. J Natl Cancer Inst 1982;68:771–778.
570 TESTING DRUG CANDIDATES FOR CYP3A4 INDUCTION